MAPREG is a start-up biotechnology company set up by Etienne E Baulieu and his research team, which has succeeded in identfying a novel mechanism for the protection and repair of nerve connections with considerable therapeutic potential.

The first therapeutic applications address acute lesions, namely Spinal Cord Injury, Traumatic Brain Injury and Stroke, for which there is presently no efficient drug. In the future, drugs with the same mechanism of action will be developed against Neurodegenerative diseases.

The present candidate drug is named MAP4343, it is a neurosteroid derivative. It currently undergoes regulatory preclinical trials.
MAP4343 has been granted orphan status for the Spinal Cord Injury indication by EMEA.
Phase 1 is scheduled by the end of 2008

UPDATING IN PROGRESS ...